Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

bone medical ltd-spons adr (BMEDY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
12.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BONE MEDICAL LTD-SPONS ADR (BMEDY)

Related News

No related news articles were found.

bone medical ltd-spons adr (BMEDY) Related Businessweek News

No Related Businessweek News Found

bone medical ltd-spons adr (BMEDY) Details

Bone Medical Limited, a specialty biopharmaceutical company, develops therapeutics to prevent and/or treat bone and joint diseases and conditions, primarily osteoporosis, osteoarthritis, and rheumatoid arthritis. The company’s product pipeline consists of Phase II clinical-stage programs and four preclinical programs. Its priority products include CaPTHymone, an oral parathyroid hormone for the treatment of osteoporosis; Capsitonin, an oral calcitonin for the treatment of osteoarthritis pain; and BN006, a synthetic oligopeptide with selective TNF-a and IL-6 inhibitory mechanism and the potential for oral administration. The company is based in West Perth, Australia.

bone medical ltd-spons adr (BMEDY) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: A$100.9K
Compensation as of Fiscal Year 2013.

bone medical ltd-spons adr (BMEDY) Key Developments

Bone Medical Limited Announces BN006 Research Collaboration with William Harvey Research Limited

Bone Medical Limited announced that it has entered into a research agreement with William Harvey Research Limited (WHRL), to further study the company's novel anti-inflammatory molecule for rheumatoid arthritis (RA), BN006, and support its progress towards clinical studies in man. The collaboration is funded under Bone Medical's recently completed recapitalization and the results will potentially position BN006 for Phase 1 human trials in the near future.

Bone Medical Ltd. Replaces Mark Clements with Phillip Wingate as Company Secretary; Changes Registered Office Address

Bone Medical Ltd. announced that Mr. Mark Clements has resigned from the position of Company Secretary. Mr. Phillip Wingate has been appointed as Company Secretary of the company following Mr. Clements resignation. The company also announced that the registered office changed to Ground Floor, 16 Ord Street, West Perth WA 6005.

Bone Medical Ltd. Announces Board Changes

Bone Medical Ltd. announced that Mr. Robert Towner has been appointed as Non-Executive Chairman and Mr. John Hannaford, Non-Executive Director of Bone's Board of Directors. Mr. Leon Ivory and Professor Peter Brooks have resigned from the Board and Dr. Roger New has resigned as Chairman but will continue as a Director effective 24 January 2014. Bone's Board and Management would like to thank Mr. Ivory and Professor Brooks for their long service to the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMEDY:US $0.00 USD 0.00

BMEDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BMEDY.
View Industry Companies
 

Industry Analysis

BMEDY

Industry Average

Valuation BMEDY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BONE MEDICAL LTD-SPONS ADR, please visit www.bone-ltd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.